Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

REGN vs INSM: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

REGN Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 9–1 Matrix Metrics)

REGN Overall Winner 6-Pillar Tally: REGN 6 – 0 INSM Matrix Metrics: REGN 9 – 1 INSM

As of Nov 19, 2026, Regeneron Pharmaceuticals Inc (REGN) is the stronger overall head-to-head candidate over Insmed, Inc. (INSM) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). REGN carries a Unified Composite Score of 42.6/100 (HOLD) at $923.34 (14.9x Forward P/E, 30.4% operating margin), whereas INSM carries 35.9/100 (SELL) at $144.46 (N/M Forward P/E, -41.7% operating margin).

  • Growth vs. Quality Trade-Off: REGN earns the overall head-to-head edge with a stronger Unified Composite Score (42.6/100 HOLD vs. INSM 35.9/100 SELL) and 0.32β · 55% Vol risk profile, whereas INSM leads top-line expansion (+268.4% YoY revenue growth, 1.09x PEG, and 0 of 6 institutional pillars) for higher-beta growth mandates.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About REGN vs INSM
REGN NASDAQ Head-to-Head Winner
Regeneron Pharmaceuticals Inc
Pharmaceutical Preparations
$923.34
-2.35% 1D
Market Cap $97.8B
TTM Revenue $16.9B
Forward P/E 14.9x
Beta / 30D Vol 0.32β · 55% Vol
Unified Composite Score
42.6 / 100 HOLD
Tech 19.0 Fund 45.0 Flow 68.0 Mom 56.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (4.5% over 20 days), RSI 58
RSI-14: 57.9 · SMA20: $907.12 · SMA50: $826.97
INSM NASDAQ
Insmed, Inc.
Pharmaceutical Preparations
$144.46
+20.58% 1D
Market Cap $26.3B
TTM Revenue $1.52B
Forward P/E N/M
Beta / 30D Vol 0.40β · 90% Vol
Unified Composite Score
35.9 / 100 SELL
Tech 5.0 Fund 35.0 Flow 66.0 Mom 40.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 77
RSI-14: 77.2 · SMA20: $112.72 · SMA50: $110.86

6-Pillar Scorecard Institutional Category Breakdown (REGN 6 – 0 INSM)

Columns: Metric · REGN · INSM
1. Valuation Multiples REGN
Forward P/E 14.9x N/M
Trailing P/E 20.9x 107.5x
PEG Ratio 1.15x 1.09x
EV / Revenue 5.7x 17.4x
2. Growth & Scale REGN
Revenue Growth (YoY) +36.3% +268.4%
Earnings Growth (YoY) +35.5% +0.0%
TTM Revenue (USD) $16.9B $1.52B
Market Cap $97.8B $26.3B
3. Profitability & Quality REGN
Gross Margin 46.7% 84.4%
Operating Margin 30.4% -41.7%
Net Profit Margin 28.5% -39.9%
Return on Equity (ROE) 14.9% -72.5%
4. Balance Sheet & Cash Flow REGN
Cash Generation (TTM) $3.63B -$628M
Cash Flow Margin 21.5% -41.3%
Net Cash / Leverage $952M Net Cash $188M Net Debt (0.81x D/E)
Dividend Yield 0.39% None (0.00%)
5. Options & Positioning REGN
Options Structure Phase CONSOLIDATION CONSOLIDATION
Current IV / %ile 35.5% (6th %ile) 52.5% (38th %ile)
Put/Call OI Skew 0.47x (Call-Skewed) 0.16x (Call-Skewed)
OBV Trend / Tech Phase ACCUMULATION · Markup ACCUMULATION · Neutral
6. R&D & Supply-Chain Moat REGN
OpEx & R&D Intensity 16.3% of Rev ($2.75B) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: REGN (9) vs INSM (1)
Institutional Metric REGN INSM Criterion Row Edge
Market Capitalization
Scale
$97.8B $26.3B Larger Scale REGN
Trailing P/E Ratio
Valuation
20.9x 107.5x Lower Multiple REGN
Forward P/E Ratio
Valuation
14.9x N/M Lower Multiple REGN
Revenue Growth (YoY)
Growth
+36.3% +268.4% Higher Growth INSM
Operating Margin (TTM)
Profitability
30.4% -41.7% Higher Margin REGN
Net Profit Margin
Profitability
28.5% -39.9% Higher Margin REGN
Return on Equity (ROE)
Capital Efficiency
14.9% -72.5% Higher ROE REGN
52-Week Range Position
Momentum
83% ($592–$992) 44% ($90–$213) Stronger Trend REGN
Beta / 30D Volatility
Risk Regime
0.32β · 55% Vol 0.40β · 90% Vol Lower Realized Risk REGN
Unified Institutional Score
Composite Signal
42.6 / 100 (HOLD) 35.9 / 100 (SELL) Higher Composite REGN
Trailing 12M Revenue (USD)
Operating Scale
$16.9B $1.52B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
46.7% 84.4% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.15x PEG · 5.7x EV/Rev 1.09x PEG · 17.4x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$3.63B ($952M Net Cash) -$628M ($188M Net Debt (0.81x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon INSM +39.01 pp
REGN: +14.61% · INSM: +53.62%
3M Horizon INSM +4.15 pp
REGN: +10.71% · INSM: +14.86%
6M Horizon REGN +11.8 pp
REGN: +43.69% · INSM: +31.89%
1Y Horizon REGN +55.65 pp
REGN: +27.3% · INSM: -28.35%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period REGN Revenue INSM Revenue REGN Op. Margin INSM Op. Margin Margin Leader
FY2018 $5.15B $10M 49.3% -3124.9% REGN
FY2019 $6.56B $140M 33.7% -172.4% REGN
FY2020 $8.50B $160M 42.1% -161.3% REGN
FY2021 $16.1B $190M 55.7% -199.0% REGN
FY2022 $12.2B $250M 38.9% -186.4% REGN
FY2023 $13.1B $310M 30.9% -232.5% REGN
FY2024 $14.2B $360M 28.1% -241.5% REGN
FY2025 $14.3B $610M 24.9% -205.6% REGN

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
REGN CONSOLIDATION
55d in phase · OBV ACCUMULATION
Current IV 35.5%
IV Percentile 6th %ile
Put/Call OI Skew 0.47x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact REGN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
INSM CONSOLIDATION
72d in phase · OBV ACCUMULATION
Current IV 52.5%
IV Percentile 38th %ile
Put/Call OI Skew 0.16x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact INSM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $952.40 · IV 33.5%

REGN vs. INSM: Simulated 5-Day Option Payoffs & Capital Efficiency

Compare 100 shares of REGN ($95,240) vs. INSM ($12,288) against risk-defined 5-day vertical and put-wall option structures.

REGN Spot $952.40 · IV 33.5%
REGN Options Simulator →
5-DAY BULLISH SWING Liq C

Dec 18 $950 / $1,000 Bull Call Spread

Buy 1x $950C · Sell 1x $1,000C · 31d

Net Entry $2,387 Debit
T+5d @ +5% Move +$891 (+37%)
Max Risk / Buffer $2,387 Capped
5d Edge & Liquidity 0.8x R:R · Liq C
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq C

Jan 15 '27 $880 / $820 Bull Put Spread

Sell 1x $880P · Buy 1x $820P · 59d

Net Entry $1,367 Credit
Max Credit / Yield +$1,367 (+29.5% RoM)
Max Risk / Buffer -9.0% Cushion ($4,633 Mgn)
5d Edge & Liquidity 75% PoP · Liq C
Simulate 5-Day Payoff →
INSM Spot $122.88 · IV 50.1%
INSM Options Simulator →
5-DAY BULLISH SWING Liq B

Dec 18 $125 / $135 Bull Call Spread

Buy 1x $125C · Sell 1x $135C · 32d

Net Entry $360 Debit
T+5d @ +5% Move +$119 (+33%)
Max Risk / Buffer $360 Capped
5d Edge & Liquidity 0.8x R:R · Liq B
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq C

Jan 15 '27 $110 / $100 Bull Put Spread

Sell 1x $110P · Buy 1x $100P · 60d

Net Entry $215 Credit
Max Credit / Yield +$215 (+27.4% RoM)
Max Risk / Buffer -12.2% Cushion ($785 Mgn)
5d Edge & Liquidity 75% PoP · Liq C
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
REGN Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $97.8B market capitalization and 30.4% operating margin.
OpEx & R&D Reinvestment 16.3% of Rev ($2.75B)
90D Engineering Disclosures 0 Published
INSM Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $26.3B market capitalization and -41.7% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ REGN vs INSM Key Questions & Quantitative Answers

As of Nov 19, 2026, Regeneron Pharmaceuticals Inc (REGN) is the stronger overall head-to-head candidate over Insmed, Inc. (INSM) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). REGN carries a Unified Composite Score of 42.6/100 (HOLD) at $923.34 (14.9x Forward P/E, 30.4% operating margin), whereas INSM carries 35.9/100 (SELL) at $144.46 (N/M Forward P/E, -41.7% operating margin). Growth vs. Quality Trade-Off: REGN earns the overall head-to-head edge with a stronger Unified Composite Score (42.6/100 HOLD vs. INSM 35.9/100 SELL) and 0.32β · 55% Vol risk profile, whereas INSM leads top-line expansion (+268.4% YoY revenue growth, 1.09x PEG, and 0 of 6 institutional pillars) for higher-beta growth mandates.

REGN leads the Growth & Scale pillar: REGN posts +36.3% YoY revenue growth and +35.5% YoY earnings growth on $16.9B TTM revenue (46.7% gross margin, 30.4% operating margin), compared with INSM at +268.4% YoY revenue growth and +0.0% YoY earnings growth on $1.52B TTM revenue (84.4% gross margin, -41.7% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), REGN cumulative revenue shifted +178.4% while INSM shifted +6000.0%. In operating R&D and SG&A reinvestment, REGN deploys 16.3% of Rev ($2.75B) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for INSM.

REGN screens cheaper on headline valuation multiples. REGN trades at 14.9x Forward P/E, 20.9x Trailing P/E, 1.15x PEG, and 5.7x EV/Revenue (21.5% FCF margin), whereas INSM trades at N/M Forward P/E, 107.5x Trailing P/E, 1.09x PEG, and 17.4x EV/Revenue (-41.3% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against REGN (14.9% ROE) versus INSM (-72.5% ROE) capital efficiency.

In options market volatility and institutional positioning, REGN carries 35.5% implied volatility (6th %ile, Compressed (<25th %ile)), a 0.47x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.32β · 55% Vol realized risk). By comparison, INSM carries 52.5% implied volatility (38th %ile, Balanced (25th–60th %ile)), a 0.16x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.40β · 90% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.